Praluent 150 MG/ML penml
Ended Awarded
- Contract number
- SPE2DB26FULZC
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,529
Award facts
- Contract value 100% obligated
- $2,529.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,529.23 to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of PRALUENT 150 mg/ml pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by November 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a direct task order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle extending through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor with an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's demonstrated capability to fulfill federal medical supply requirements through open competition, combined with its large prime indefinite delivery contract with DLA, positions it as a primary supplier for military and veteran healthcare systems. PRALUENT, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is a biologic medication used to treat high cholesterol in patients with cardiovascular disease, reflecting the specialized pharmaceutical support the contractor provides to federal healthcare beneficiaries.
Quick answers
Who was awarded contract SPE2DB26FULZC?
SPE2DB26FULZC was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DB26FULZC worth?
The government has obligated $2,529 on SPE2DB26FULZC.
Is contract SPE2DB26FULZC an order under another contract?
Yes. SPE2DB26FULZC is a delivery order under SPE2DB25D3404, an indefinite delivery contract.
Was contract SPE2DB26FULZC competed?
The extent of competition for SPE2DB26FULZC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award